Pharmaceutical Partnerships
Pharmaceutical Out-Licensing
Expanding Patient Access to our Medical Nutrition range and Laxido Branded Products worldwide through strategic global partnerships
We leverage our deep understanding of the healthcare industry and our extensive experience in navigating the complexities of achieving commercial success within the pharmaceutical sector. Our expertise allows us to offer robust out-licensing opportunities that can drive growth and innovation for you.
By partnering with us, you can access commercially viable pharmaceutical products without the substantial investment typically required for research and development. This not only reduces your costs but also accelerates your time to market, allowing you to enter and compete more quickly.
The products we have available for out-licensing are designed to meet the highest standards of quality and innovation, ensuring that you can confidently bring new solutions to your customers. The collaborative nature of out-licensing helps mitigate risks, providing you with support through our proven processes in regulatory approval and commercialisation. This strategic approach fosters long-term growth and creates valuable partnerships, ultimately leading to our shared success.
By working with us, you benefit from our proven track record of successfully commercialising and managing pharmaceutical products worldwide. Together, we can achieve greater innovation, market expansion, and mutual success in the ever-evolving pharmaceutical landscape.
We are committed to bringing innovation, quality and customer focus to people with metabolic disorders.
Galen offers a variety of innovative foods for special medical purposes, for use in the dietary management of inborn errors of metabolism including:
Galen manufactures a range of Laxido products which includes Laxido Orange and Laxido Paediatric Plain.
Galen manufactures a branded generic range of Laxido products which includes Laxido Orange and Laxido Paediatric Plain.
Laxido Orange is a sugar free laxative used to treat chronic constipation and faecal impaction in adults, adolescents and the elderly.
“We believe that everyone should have the right to access appropriate health care. Finding innovative solutions to improve access to medicines and treatments is the biggest challenge for many patients today. Through our work with Galen and our commitment and daily efforts, we help people overcome this challenge and help them live longer and be healthier." - CEO Ala Tocarciuc
Galen Limited
Seagoe Industrial Estate
Craigavon
BT63 5UA
United Kingdom
Telephone:+44 (0)28 3833 4974
Email:
POA Pharma Scandinavia AB
Banevænget 13, 1.
3460 Birkerød
Denmark
Telephone: +45 3117 4300
Email:
POA Pharma GmbH
Langenbruchstraße 20A
D-45549 Sprockhövel
Germany
Telephone: +49 (0)2339 9113404
Email: